About Cellectis
Cellectis is a publicly listed company based in Paris (France) founded in 1999. Cancer immunotherapies are developed via gene-edited CAR T-cells. It operates on a HealthTech model. The company has 222 employees. Cellectis has completed 1 acquisition, including Cellartis. Its website cellectis.com draws about 10 thousand monthly visits. Cellectis offers products and services including TALEN® Technology and Allogeneic CAR T Therapies. Its focus areas include Biotechnology and Gene Therapy.
Company details
Cellectis is engaged in the development of innovative gene-editing solutions using its proprietary TALEN technology. The company specializes in creating allogeneic CAR T-cell therapies aimed at treating cancer through off-the-shelf immunotherapies. Its technologies are applied in clinical settings to address challenges like Graft vs. Host Disease and therapy rejection. Strategic partnerships with organizations such as Allogene and AstraZeneca are maintained to enhance research and development. Solutions are explored for various diseases beyond cancer, leveraging 25 years of innovation in the biotechnology sector.
- Headquarters Paris, France
- Employees 222
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website cellectis.com
- Social LinkedIn X Facebook
- Legal Name Cellectis S.A.
- Annual Revenue$75.95 M (USD)68.46as on Dec 31, 2025
- Net Profit-$70.37 M (USD)-76.23as on Dec 31, 2025
- EBITDA-$21.13 M (USD)59.68as on Dec 31, 2025
- Latest Funding Round$140M (USD), Post-IPO
May 2024
- InvestorsAstrazeneca
& 5 more
- Employee Count222
- Investments & Acquisitions
Products & Services of Cellectis
Cellectis offers a comprehensive portfolio of products and services, including TALEN® Technology and Allogeneic CAR T Therapies.
TALEN® technology is used for precise gene editing.
Off-the-shelf CAR T therapies are developed for cancer.
Funding Insights of Cellectis
- Total Rounds 3
- Last Round Post-IPO — $140M
- First Round $22.45M
(Mar 2014)
- Investors Count 6
All 3 funding rounds of Cellectis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $140M | Post-IPO | – | – | |
| Nov 2023 | $105M | Post-IPO | – | – | |
| Mar 2014 | $22.45M | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in Cellectis
Cellectis has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Orbimed and venBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Ridgeback Capital is focused on healthcare and life science investments. | ridgebackcap.com | New York, United States | ||
| aquilocapitalmanagement.com | ||||
| merlinnexus.com | ||||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Cellectis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellectis
69 people are tracked at Cellectis (34 in leadership, 11 in board & advisors, 24 in team); the tracked headcount is 222.
| Name | Role | Group |
|---|---|---|
Arthur Stril | Chief Financial Officer (interim) / Chief Business Officer | Leadership |
Kyung Nam-Wortman | EVP & Chief Human Resources Officer | Leadership |
Steve Doares | SVP, US Manufacturing & Site Head | Leadership |
Philippe Duchateau | Chief Scientific Officer | Leadership |
Kathy Simon | Vice President Global Quality | Leadership |
André Choulika | Director & CEO | Leadership |
Stephan Reynier | Chief Regulatory and Compliance Officer | Leadership |
Wei Zhang | Director, Pharmacovigilance & Clinical Sciences | Leadership |
Mark Frattini | Chief Medical Officer | Leadership |
Shipra Das | Associate Director | Leadership |
Denise N. Thomas | Senior Director Clinical Research Scientist | Leadership |
Guillaume Bertucat | Information Systems Director | Leadership |
Sophie Derniame | Director, CMC Program Management | Leadership |
Kelley Wall | Associate Director Business IT Services | Leadership |
Patricia Sosa Navarro | Chief Of Staff To The CEO | Leadership |
Keri O'Rourke | Associate Director, Corporate IT Business Services And Training | Leadership |
Alaa Rashid | Director, US Manufacturing Operations | Leadership |
Constance Saccomandi | Senior Legal Counsel (senior Director Level) - Clinical Trials, Manufacturing Contracts | Leadership |
Aymeric Duclert | Head Of Bioinformatics Department | Leadership |
Claire Roudot | Associate Director Business Development & Alliance Management | Leadership |
49 more people are available in the full profile.
Complete people profiles for Cellectis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cellectis
Cellectis is a publicly listed company on the EURONEXT with ticker symbol ALCLS in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Mar 2015
- Listed onNASDAQ: CLLS
- Listed entityCellectis S.A.
- Exchange sectorHealth technology
- ISINFR0010425595
- Share price1.09 EUR (+3.81% on the day) · 2026-10-14
- Market capitalisation75,941,724.00 EUR
- EPS (diluted, trailing year)-0.56 EUR
- Volume (last session)148,305
Financials of Cellectis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 64.6M EUR | -59.9M EUR | -18.0M EUR |
| 2024 | 38.4M EUR | -34.0M EUR | -44.6M EUR |
| 2023 | 698,350 EUR | -93.5M EUR | -81.5M EUR |
| 2022 | 18.2M EUR | -101.0M EUR | -75.3M EUR |
| 2021 | 25.7M EUR | -96.6M EUR | -82.5M EUR |
Detailed financial statements for Cellectis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellectis
Cellectis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cellartis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Stem Cell Research Products from Takara Clontech | cellartis.com | Gothenburg, Sweden | 2004 | Sep 2011 | •••• |
Complete acquisition details for Cellectis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cellectis
5 dated milestones of Cellectis across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Cellectis is founded.
- Acquisition Acquires Cellartis.
- Funding First funding round of $22.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $140.0M.
Web traffic of Cellectis
The website of Cellectis (cellectis.com) receives about 10.1K visits a month and ranks #2,255,178 among all websites worldwide, #3,074 in Biotechnology and Pharmaceuticals.
- Monthly visits10.1K
▼ 1.3% vs previous month
- Unique visitors4.4K
per month
- Global rank#2,255,178
among all websites
- Category rank#3,074
Health · Biotechnology and Pharmaceuticals
- Bounce rate54%
- Pages per visit1.7
- Average visit30 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Cellectis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kyowakirin.com | 100% | 55K | #722,482 | View details | |
| aptose.com | 94% | 3.6K | #6,596,362 | View details | |
| legendbiotech.com | 94% | 38.1K | #1,021,456 | View details | |
investor.bluebirdbio.com | investor.bluebirdbio.com | 78% | – | ||
| innate-pharma.com | 78% | 10.5K | #2,074,647 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Cellectis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellectis
Complete news archive for Cellectis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellectis
Cellectis was founded in 1999 and raised its 1st funding round 15 years after it was founded.
Cellectis is headquartered in Paris, France.
Cellectis has 222 employees.
Annual revenue of Cellectis is $75.95M as on Dec 31, 2025.
Cellectis is engaged in the development of innovative gene-editing solutions using its proprietary TALEN technology. The company specializes in creating allogeneic CAR T-cell therapies aimed at treating cancer through off-the-shelf immunotherapies. Its technologies are applied in clinical settings to address challenges like Graft vs. Host Disease and therapy rejection. Strategic partnerships with organizations such as Allogene and AstraZeneca are maintained to enhance research and development. Solutions are explored for various diseases beyond cancer, leveraging 25 years of innovation in the biotechnology sector.
Cellectis offers TALEN® Technology and Allogeneic CAR T Therapies.
Yes, Cellectis is publicly traded on EURONEXT under the ticker symbol ALCLS.
Cellectis has made 1 acquisition, including Cellartis.
Cellectis has 6 investors. Key investors include Astrazeneca, Orbimed, venBio, Ridgeback Capital, and Aquilo Capital Management.
Cellectis operates through Cellectis.